

Amendment Statement of Principles

concerning

DIABETES MELLITUS  
(Reasonable Hypothesis)

(No. 83 of 2021)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

Dated 25 June 2021

|  |
| --- |
| The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of: |
| Professor Nicholas Saunders AO  Chairperson |

Contents

1 Name 3

2 Commencement 3

3 Authority 3

4 Amendment 3

1. Name

This is the Amendment Statement of Principles concerning *diabetes mellitus* *(Reasonable Hypothesis)* (No. 83 of 2021).

1. Commencement

This instrument commences on 26 July 2021.

1. Authority

This instrument is made under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

1. Amendment

The Statement of Principles concerning *diabetes mellitus* *(Reasonable Hypothesis)* (No. 48 of 2020) (Federal Register of Legislation No. F2020L00823) is amended in the following manner:

|  |  |
| --- | --- |
| **Section** | **Amendment** |
| *9(6)(g)* | *Replace the existing factor in paragraph 9(6)(g) with the following*:  taking an immune checkpoint inhibitor or an interferon within the one year before the clinical onset of diabetes mellitus;  Note: Examples of immune checkpoint inhibitors include ipilumab, tremelimumab, nivolumab and pembrolizumab. |
| *9(6)(h)* | *Delete the existing note to paragraph 9(6)(h).* |
| *9(13a)* | *Insert the following new factor at subsection 9(13a):*  taking an immune checkpoint inhibitor or an interferon within the one year before the clinical worsening of diabetes mellitus;  Note: Examples of immune checkpoint inhibitors include ipilumab, tremelimumab, nivolumab and pembrolizumab. |
| *Schedule 1 – Dictionary* | *Delete the existing definition of* ***having infection with a Coxsackie B virus***. |